Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactions.

Zheng N, Christopher LJ, Ma X, Ji QC, Buzescu A, Kandoussi H, Garonzik SM, LaCreta F, Aubry AF, Arnold ME, Zeng J.

Bioanalysis. 2016 Dec;8(23):2429-2443.

PMID:
27855510
2.

A validated LC-MS/MS method for the quantitative measurement of creatinine as an endogenous biomarker in human plasma.

Zhao Y, Liu G, Angeles A, Christopher LJ, Wang Z, Arnold ME, Shen JX.

Bioanalysis. 2016 Oct;8(19):1997-2005. doi: 10.4155/bio-2016-0086. Epub 2016 Sep 9.

PMID:
27611058
3.

Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression.

Shen H, Liu T, Morse BL, Zhao Y, Zhang Y, Qiu X, Chen C, Lewin AC, Wang XT, Liu G, Christopher LJ, Marathe P, Lai Y.

Drug Metab Dispos. 2015 Jul;43(7):984-93. doi: 10.1124/dmd.114.062364. Epub 2015 Apr 22.

PMID:
25904762
4.

Reflecting on a decade of metabolite screening and monitoring.

Aubry AF, Christopher LJ, Wang J, Zhu M, Tirucherai G, Arnold ME.

Bioanalysis. 2014 Mar;6(5):651-64. doi: 10.4155/bio.14.19. Review.

PMID:
24620807
5.

Sensitivity-based analytical approaches to support human absolute bioavailability studies.

Xu XS, Jiang H, Christopher LJ, Shen JX, Zeng J, Arnold ME.

Bioanalysis. 2014 Feb;6(4):497-504. doi: 10.4155/bio.13.318.

PMID:
24568352
6.

The synthesis of a carbon-14 labeled pegylated Adnectin™ for placental transfer studies in guinea pigs.

Maxwell BD, Cao K, Bonacorsi S, Sivaraman L, Wang B, McNerney M, Wang L, Christopher LJ, Fung NK, Wang J, Arnold ME.

J Labelled Comp Radiopharm. 2013 Jul-Aug;56(9-10):492-4. doi: 10.1002/jlcr.3077. Epub 2013 Jul 16.

PMID:
24285527
7.

Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.

Yang Z, Vakkalagadda B, Shen G, Ahlers CM, Has T, Christopher LJ, Kurland JF, Roongta V, Masson E, Zhang S.

J Clin Pharmacol. 2013 Feb;53(2):217-27. doi: 10.1177/0091270012439208.

PMID:
23436267
8.

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.

Xu XS, Dueker SR, Christopher LJ, Lohstroh PN, Keung CF, Cao KK, Bonacorsi SJ, Cojocaru L, Shen JX, Humphreys WG, Stouffer B, Arnold ME.

Bioanalysis. 2012 Aug;4(15):1855-70. doi: 10.4155/bio.12.171.

PMID:
22943617
9.

Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.

Boulton DW, Kasichayanula S, Keung CF, Arnold ME, Christopher LJ, Xu XS, Lacreta F.

Br J Clin Pharmacol. 2013 Mar;75(3):763-8. doi: 10.1111/j.1365-2125.2012.04391.x.

10.

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.

Su H, Boulton DW, Barros A Jr, Wang L, Cao K, Bonacorsi SJ Jr, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2012 Jul;40(7):1345-56. doi: 10.1124/dmd.112.045450. Epub 2012 Apr 10.

PMID:
22496391
11.

Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.

Xu XS, Demers R, Gu H, Christopher LJ, Su H, Cojocaru L, Boulton DW, Kirby M, Stouffer B, Humphreys WG, Arnold ME.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 15;889-890:77-86. doi: 10.1016/j.jchromb.2012.01.033. Epub 2012 Feb 6.

PMID:
22349123
12.

In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.

Hong H, Su H, Ma L, Yao M, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2011 Sep;39(9):1658-67. doi: 10.1124/dmd.111.039776. Epub 2011 Jun 14.

PMID:
21673131
13.

Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.

Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, Iyer RA.

Drug Metab Dispos. 2011 May;39(5):891-903. doi: 10.1124/dmd.110.037341. Epub 2011 Feb 2.

PMID:
21289073
14.

Development and evaluation of a multiple-plate fraction collector for sample processing: application to radioprofiling in drug metabolism studies.

Barros A Jr, Ly VT, Chando TJ, Ruan Q, Donenfeld SL, Holub DP, Christopher LJ.

J Pharm Biomed Anal. 2011 Apr 5;54(5):979-86. doi: 10.1016/j.jpba.2010.11.029. Epub 2010 Nov 27.

PMID:
21168298
15.

Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine.

Hong H, Caceres-Cortes J, Su H, Huang X, Roongta V, Bonacorsi S Jr, Hong Y, Tian Y, Iyer RA, Humphreys WG, Christopher LJ.

Chem Res Toxicol. 2011 Jan 14;24(1):125-34. doi: 10.1021/tx100337s. Epub 2010 Nov 16.

PMID:
21080678
16.

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.

Christopher LJ, Hong H, Vakkalagadda BJ, Clemens PL, Su H, Roongta V, Allentoff A, Sun H, Heller K, Harbison CT, Iyer RA, Humphreys WG, Wong T, Zhang S.

Drug Metab Dispos. 2010 Nov;38(11):2049-59. doi: 10.1124/dmd.110.034850. Epub 2010 Jul 28.

PMID:
20668249
17.

Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.

Hong H, Su H, Sun H, Allentoff A, Ekhato IV, Chando T, Caceres-Cortes J, Roongta V, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2010 Jul;38(7):1189-201. doi: 10.1124/dmd.110.032755. Epub 2010 Apr 2.

PMID:
20363952
18.

Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.

Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, Boulton DW, Christopher LJ, Chadwick KD, Hamann LG, Humphreys WG, Kirby M.

Drug Metab Dispos. 2009 Jun;37(6):1164-71. doi: 10.1124/dmd.108.026088. Epub 2009 Feb 27.

PMID:
19251818
19.

Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.

He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2008 Dec;36(12):2564-70. doi: 10.1124/dmd.108.022764. Epub 2008 Sep 11.

PMID:
18787054
20.

Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics.

Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D.

Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12.

PMID:
18556438
21.

Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.

Christopher LJ, Cui D, Li W, Barros A Jr, Arora VK, Zhang H, Wang L, Zhang D, Manning JA, He K, Fletcher AM, Ogan M, Lago M, Bonacorsi SJ, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2008 Jul;36(7):1341-56. doi: 10.1124/dmd.107.018234. Epub 2008 Apr 17.

PMID:
18420785
22.

Metabolism and disposition of dasatinib after oral administration to humans.

Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17.

PMID:
18420784
23.

6-Acylamino-2-[(alkylsulfonyl)oxy]-1H-isoindole-1,3-dione mechanism-based inhibitors of human leukocyte elastase.

Kerrigan JE, Walters MC, Forrester KJ, Crowder JB, Christopher LJ.

Bioorg Med Chem Lett. 2000 Jan 3;10(1):27-30.

PMID:
10636236
24.

Cloning and identification of Arp1, an actin-related protein from Pneumocystis carinii.

Christopher LJ, Fletcher LD, Dykstra CC.

J Eukaryot Microbiol. 1995 Mar-Apr;42(2):142-9.

PMID:
7757056
25.

Identification of a type II topoisomerase gene from Cryptosporidium parvum.

Christopher LJ, Dykstra CC.

J Eukaryot Microbiol. 1994 Sep-Oct;41(5):28S. No abstract available.

PMID:
7804230
26.

Duplicate prescriptions: an aid to research and review.

Hamley JG, Brown SV, Crooks J, Christopher LJ, Dingwall D, Murdoch JC, Knox JD, Patterson AW.

J R Coll Gen Pract. 1981 Nov;31(232):648-50.

27.

Patterns of drug prescribing for children in hospital.

Moreland TA, Rylance GW, Christopher LJ, Stevenson IH.

Eur J Clin Pharmacol. 1978 Nov 9;14(1):39-46.

PMID:
729605
28.

Taking drugs during pregnancy.

Christopher LJ.

Dev Med Child Neurol. 1978 Jun;20(3):380-3. No abstract available.

PMID:
669068
29.

Drug prescribing patterns in the elderly: a cross-sectional study of in-patients.

Christopher LJ, Ballinger BR, Shepherd AM, Ramsay A, Crooks G.

Age Ageing. 1978 May;7(2):74-82.

PMID:
307335
30.

Transcription errors in the drug information supplied from hospital to general practitioners.

Wilkin TJ, Dodd W, Christopher LJ, Crooks J.

Health Bull (Edinb). 1978 Jan;36(1):13-6. No abstract available.

PMID:
624623
31.

A multicentre study of rauwolfia derivates and breast cancer.

Christopher LJ, Crooks J, Davidson JF, Erskine ZG, Gallon SC, Moir DC, Weir RD.

Eur J Clin Pharmacol. 1977 Jul 19;11(6):409-17. No abstract available.

PMID:
891584
32.

Rauwolfia derivatives and breast cancer.

Christopher LJ, Crooks J, Moir D, Weir RD.

Lancet. 1977 Jan 15;1(8003):140-1. No abstract available.

PMID:
64670
33.

Aberdeen-Dundee medicines evaluation and monitoring group [proceedings].

Wier RD, Moir DC, Erskine ZG, Gallon SC, Davidson JF, Crooks J, Christopher LJ.

Br J Pharmacol. 1976 Oct;58(2):317P. No abstract available.

34.

A hospital based drug information system.

Moir DC, Alexander ER, Barnett JW, Christopher LJ.

Health Bull (Edinb). 1975 Mar;33(2):82-8. No abstract available.

PMID:
1165191
35.

A trial of hippramine in the treatment of bacteriuria of pregnancy.

Christopher LJ, Thompson GR.

Ir J Med Sci. 1969 Jul;8(7):331-7. No abstract available.

PMID:
5806178
36.

A controlled trial of laxatives in geriatric patients.

Christopher LJ.

Practitioner. 1969 Jun;202(212):821-5. No abstract available.

PMID:
4894318

Supplemental Content

Loading ...
Support Center